Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Dare Bioscience, Inc.

DARENASDAQEQUITYCurrent

Changes in Beneficial Ownership

Filed Nov 20, 2026Accepted Nov 20, 2026, 4:05 PM ESTFiling CIK 1401914Accession 0001493152-26-053477
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-11-19
Issuer
Dare Bioscience, Inc.
Issuer CIK
0001401914
Trading symbol
DARE

Reporting owner 1

Name
RASTETTER WILLIAM H
Reporting owner CIK
0001205903
Relationship
Director
Address
3655 NOBEL DRIVE, SUITE 260, SAN DIEGO, CA, 92122

Non-derivative transactions

Non-derivative transactions · 1 reported row
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common stock2026-11-19S · Form 4859[F1]D0.4450D
Table key
S · Form 4
Sale on the market or privately
D
Direct

Footnotes

F1
These shares were sold by the Reporting Person for personal tax planning purposes prior to the end of the calendar year.↩ 1

Signature 1

Signed
/s/ Sabrina Martucci Johnson, Attorney-in-fact
Date
2026-11-20

Company context

We are a purpose-driven health biotech company solely focused on closing the gap in women’s health between promising science and real-world solutions. Every innovation we advance is based in advanced science and backed by rigorous, peer-reviewed research. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we’re working to close critical gaps in care using science that serves her needs. In March 2025, we announced an expansion of our business model to include a dual-path approach to bringing new products to market. For select proprietary formulations, we are pursuing both traditional FDA approval and earlier market access via Section 503B compounding. We believe this strategy allows us to respond to clinician and patient demand for timely access while continuing to generate the data necessary to seek FDA approval and support long-term value creation. In addition to prescription-based offerings — both FDA-approved products and compounded drugs — we intend to bring to market select consumer health products that do not require a physician’s prescription, where appropriate based on product profile and market opportunity.

Current securities

Recent company filings

  1. 144 filingNov 19, 2026
  2. Results of Operations and Financial ConditionNov 16, 2026
  3. 10-Q filingNov 16, 2026
  4. Submission of Matters to a Vote of Security HoldersNov 12, 2026
  5. DEFA14A filingOct 27, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.